Shanghai Fudan Forward S&T Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.69, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.44, suggesting it can cover short-term obligations but with limited buffer. The price-to-book ratio of 3.75 implies the market values the company at a premium to its book value, while the negative operating and net income figures indicate a lack of profitability. Profitability metrics show a return on equity of -0.006 and a return on assets of -0.0029, both of which are negative and significantly below the industry norms for pharmaceutical companies. The gross profit margin of 35.8% is in line with the industry average, but the operating loss of 7.25 million CNY and net loss of 4.66 million CNY highlight operational inefficiencies. The company's revenue is concentrated in a single geographic market, China, with no disclosed segment breakdown. This concentration increases exposure to local regulatory and economic risks. There is no information on revenue diversification across product lines or therapeutic areas. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The operating cash flow is negative at -51.34 million CNY, and capital expenditures are minimal at -1.81 million CNY, suggesting limited investment in future capacity. Analyst estimates for revenue and EPS are below the company's reported figures, indicating a potential decline in performance. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could constrain its ability to fund operations without external financing. No significant dilution events are expected in the near term, and the company has not issued new shares recently. Recent events include the publication of the latest financial results, which show a net loss and negative operating cash flow. There are no disclosed major regulatory changes or product launches in the recent filings or transcripts.